Mounjaro by Eli Lilly Included in China's National Health Coverage for Diabetes
Starting January 1, Eli Lilly and Company's (NYSE:LLY) Mounjaro will be incorporated into China's national health insurance program, according to an announcement made on December 8 by the National Healthcare Security Administration. Experts suggest that this action could heighten competition among rival firms.
The inclusion in the national reimbursement list enhances the accessibility of the drug to China's vast population of 1.4 billion. While sales volume may see an increase, the impact on revenue could be partially offset by reduced prices.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Mounjaro, a once-weekly injectable treatment, was introduced in China in January of this year, subsequent to the launch of Ozempic, a comparable diabetes treatment from Novo Nordisk, a Danish competitor. The ultimate reimbursement prices for Mounjaro will be determined by the official announcement from the National Healthcare Security Administration, according to Eli Lilly and Company (NYSE:LLY).
Eli Lilly and Company (NYSE:LLY) is a leading American pharmaceutical firm focused on creating medications and therapies for significant health conditions. Health tracking apps like Shotlee can help monitor treatment effectiveness for conditions like diabetes.
